Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review

Experimental and Clinical Cardiology

Volumn 13, Issue 4, 2008, Pages 192-197

  Hashemzadeh, Mehrnoosh ^a   Furukawa, Matthew ^b   Goldsberry, Sarah ^b   Movahed, Mohammad Reza ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b WHITTIER COLLEGE   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Acute coronary syndrome; Antagonist; Antiplatelet; Antithrombotic; Glycoprotein IIb IIIa receptor; Stenting

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBUS; UNITED STATES;

EID: 63449116968     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Gulba DC, Huber K, Moll S, Dietz R. Platelet inhibition: New agents, new strategies, new trials. Fibrinolysis and Proteolysis 1998;12(Suppl2):13-23.
2. Coller B. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80.
3. Schrör K, Weber A. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolys 2003;15:71-80.
4. Kereiakes D, Runyon J, Broderick T, Shimshak T IIb's are not IIbs. Am J Cardiol 2000;85:23C-31C.
5. Peter K. Principles of Molecular Cardiology. Totowa: Humana Press, 2005.
6. Massberg S, Mueller I, Besta F, Thomas P, Gawaz M. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on Platelet function in patients undergoing coronary stenting. Am Heart J 2003;146:el9.
7. Cazenave J, Gachet C. Anti-platelet drugs: Do they affect megakaryocytes? Bailliere's Clin Haematol 1997; 10: 163-80.
8. Agah R, Plow EF, Topol EJ. [alpha]IIb[beta]3 (GPPIIb-IIIa) Antagonists. Platelets, 2nd edn. London: Elsevier Inc, 2007:1145-63.
9. Darius H. Oral glycoprotein IIb/IIa antagonists for unstable angina - Is there still a chance for the oral substances? Thromb Res 2001;103:117-24.
10. Tcheng J. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000; 139:S38-45.
11. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Curr Drug Targets Cardiovasc Haematol Disord 2008;8:138-46.
12. Pollack CV Jr, Hollander JE. Antiplatelet therapy in acute coronary syndromes: The emergency physician's perspective. J Emerg Med 2008;35:5-13.
13. Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2000;102:1093-100.
14. Lefebvre CW, Hoektra JW, Bonaca M, Giugliano R. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with Non-ST-Elevation acute coronary syndromes: Principles and practices. J Emerg Med 2008.
15. Servoss SJ, Wan Y, Snapinn SM, et al. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. Am J Cardiol 2004;93:843-7.
16. Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002;105:2361-6.
17. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354:1757-62.
18. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003;91:17-21.
19. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprootein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New Engl J Med 2001;344:1888-94.
20. Gunasekara AP, Walters DL, Aroney CN. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention. Int J Cardiol 2006; 109:16-20.
21. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The ADVANCE Trial. J Am Coll Cardiol 2004;44:14-9.
22. Danzi GB, Capuano C, Sesana M, Baglini R. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc Interv 2004;61:179-84.
23. Hassan W, Al-Sergani H, Al Buraiki J, et al. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study. Am Heart J 2007;154:345-51.
24. Marmur JD, Poludasu S, Agarwal A, et al. Bolus-only platelet glycoprotein IIb-IIla inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18:521-6.
25. Marmur JD, Poludasu S, Agarwal A, Manjappa N, Cavusoglu E. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. J Invasive Cardiol 2008;20:53-8.
26. Lev EI, Kornowski R, Teplisky I, et al. The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction. Int J of Cardiovasc Intervent 2005;7:41-45.
27. Racine E. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction. Am J Health Syst Pharm 2002;59(21 Suppl 7):S27-36.
28. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19.
29. Rocha-Singh KJ, Rutherford J. Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percuraneous intervention for symptomatic peripheral vascular disease: The circulate pilot trial. Catheter Cardiovasc Interv 2005;66:470-3.
30. Burkart DJ, Borsa JJ, Anthony JP, Thurlo SR. Thrombolysis of acute peripheral arterial and venous occlusions with tenecteplase and eptifibatide: A pilot study. J Vasc Interv Radiol 2003;14:729-33.
31. Kidane AG, Salacinski AT, Bruckdorfer KR, Seifalian AM. Anticoagulant and antiplatelet agents: Their clinical and device application(s) together with usages to engineer surfaces. Biomacromolecules 2004;5:798-813.
32. Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Am Heart J 1999;138:307-16.
33. Antoniucci D. Differences Among GP IIb/IIIa inhibitors: Different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients. Eur Heart J 2007;9:A32-6.
34. Ekmekci OB, Ekmekci H. Vitronectin in atherosclerotic disease. Clinica Chimica Acta 2006;369:77-83.
35. 3 integrins. Circulation 1998;98:1085-91.
36. Casserly I, Topol E. Glycoprotein IIb/IIIa-antagonists - from bench to practice. Cell Mol Life Sci 2002;59:1-23.
37. Li F, Spencer F, Becker R. Comparative Efficacy of fibrinogen. Am Heart J 2001;142:204-10.
38. Phillips D, SpTborough R. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80:11B-20B.
39. Topol EJ, Byzova T, Plow E. Platelet GP IIb/IIIa blockers. Lancet 1999;353:227-31.
40. Kadheinz P. Antiplatelet Drugs. In: Runge MS, ed. Principles of Molecular Cardiology, Totowa: Human Press, 2005:203-18.
41. Shanmugam G. Tirofiban and emergency coronary surgery. Eur J Cardiothorac Surg 2005;28:546-50.
42. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use? Circulatiori 1999; 100:437-44.
43. Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIa inhibitors. Am Heart J 1999; 138:S263-75.
44. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demontrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-8.